Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis

European Respiratory Journal

Volumn 46, Issue 4, 2015, Pages 1046-1054

  Barr, Helen L ^a   Halliday, Nigel ^a   Cámara, Miguel ^a   Barrett, David A ^a   Williams, Paul ^a   Forrester, Douglas L ^a   Simms, Rebecca ^a   Smyth, Alan R ^a   Honeybourne, David ^a   Whitehouse, Joanna L ^b   Nash, Edward F ^b   Dewar, Jane ^b   Clayton, Andrew ^c   Knox, Alan J ^c   Fogarty, Andrew W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 HEPTYL HYDROXYQUINOLINE; 2 NONYL 4 HYDROXYQUINOLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; 2-NONYL-4-HYDROXYQUINOLINE; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; MY 12-62C; QUINOLINOL DERIVATIVE;

ADULT; BACTERIAL LOAD; BLOOD LEVEL; CELL DENSITY; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; QUANTITATIVE ANALYSIS; QUORUM SENSING; SPUTUM LEVEL; URINE LEVEL; ADOLESCENT; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; SPUTUM; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOMARKERS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; HYDROXYQUINOLINES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLINES; QUORUM SENSING; SPUTUM; YOUNG ADULT;

EID: 84943255529     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00225214     Document Type: Conference Paper

References (32)

1. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139.
2. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
3. Williams P, Cámara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009; 12: 182-191.
4. Jaffar-Bandjee MC, Lazdunski A, Bally M, et al. Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa. J Clin Microbiol 1995; 33: 924-929.
5. Middleton B, Rodgers HC, Cámara M, et al. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol Lett 2002; 207: 1-7.
6. Struss AK, Nunes A, Waalen J, et al. Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states. Anal Chem 2013; 85: 3355-3362.
7. Smyth AR, Cifelli PM, Ortori CA, et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis - a pilot randomized controlled trial. Pediatr Pulmonol 2010; 45: 356-362.
8. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001; 139: 359-365.
9. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
11. The UK Cystic Fibrosis Trust Diabetes Working Group. Cystic Fibrosis Our Focus: Management of Cystic Fibrosis Related Diabetes Mellitus. Bromley, Cystic Fibrosis Trust, 2004. Available from: http://cysticfibrosis.org.uk/media/82028/diabetes-mellitus-management-jun04.pdf
12. The UK Cystic Fibrosis Trust Microbiology Laboratory Standards Working Group. Laboratory Standards for Processing Mircobiological Samples from People with Cystic Fibrosis. Bromley, Cystic Fibrosis Trust, 2004. Available from: www.cysticfibrosis.org.uk/media/82034/CD-Laboratory-Standards-Sep-10.pdf
13. Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52: 498-501.
14. Ortori CA, Atkinson S, Chhabra SR, et al. Comprehensive profiling of N-acylhomoserine lactones produced by Yersinia pseudotuberculosis using liquid chromatography coupled to hybrid quadrupole-linear ion trap mass spectrometry. Anal Bioanal Chem 2007; 387: 497-511.
15. Ortori CA, Dubern JF, Chhabra SR, et al. Simultaneous quantitative profiling of N-acyl-L-homoserine lactone and 2-alkyl-4(1H)-quinolone families of quorum-sensing signaling molecules using LC-MS/MS. Anal Bioanal Chem 2011; 399: 839-850.
16. Diggle SP, Lumjiaktase P, Dipilato F, et al. Functional genetic analysis reveals a 2-Alkyl-4-quinolone signaling system in the human pathogen Burkholderia pseudomallei and related bacteria. Chem Biol 2006; 13: 701-710.
17. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr-/- mice. Antimicrob Agents Chemother 2007; 51: 3677-3687.
18. Diggle SP, Griffin AS, Campbell GS, et al. Cooperation and conflict in quorum-sensing bacterial populations. Nature 2007; 450: 411-414.
19. Meyer KC, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1536-1540.
20. Palmer KL, Mashburn LM, Singh PK, et al. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol 2005; 187: 5267-5277.
21. Wilder CN, Allada G, Schuster M. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 2009; 77: 5631-5639.
22. Garske LA, Beatson SA, Leech AJ, et al. Sub-inhibitory concentrations of ceftazidime and tobramycin reduce the quorum sensing signals of Pseudomonas aeruginosa. Pathology 2004; 36: 571-575.
23. Tateda K, Comte R, Pechere JC, et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45: 1930-1933.
24. Bjarnsholt T, Jensen PØ, Jakobsen TH, et al. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One 2010; 5: e10115.
25. Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103: 8487-8492.
26. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009; 53: 3847-3854.
27. Mowat E, Paterson S, Fothergill JL, et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 2011; 183: 1674-1679.
28. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012; 7: e45001.
29. Nalca Y, Jänsch L, Bredenbruch F, et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 2006; 50: 1680-1688.
30. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 3648-3663.
31. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010; 86: 493-501.
32. Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 853-860.